SCHEMBL7284347

SCHEMBL7284347

CC(=O)c1cn(C)c2ccc(C)cc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NR4A2 P43354 6/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PRF1 P14222 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.42
KDR P35968 1/20 0.42
MITF O75030 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13774352 0.88 KDM4E (0.51) BRD4L3MBTL1NR4A2KDM4EHSD17B10
SCHEMBL12167181 0.86 KMT2A (0.56) L3MBTL1NR4A2KDM4EHSD17B10KMT2A
SCHEMBL30622587 0.86 KMT2A (0.56) L3MBTL1NR4A2KDM4EHSD17B10KMT2A
SCHEMBL14756161 0.86 BRD4 (0.49) BRD4L3MBTL1NR4A2NPC1RAB9A
SCHEMBL28131995 0.84 ICMT (0.47) NR4A2KDM4EHSD17B10KMT2AMEN1
SCHEMBL7275971 0.83 KDM4E (0.55) BRD4L3MBTL1NR4A2NPC1RAB9A
SCHEMBL9572754 0.83 KCNH2 (0.59) BRD4L3MBTL1NR4A2NPC1RAB9A
SCHEMBL6489435 0.83 BRD4 (0.46) BRD4L3MBTL1NR4A2PRF1KMT2A
SCHEMBL24182134 0.82 NR4A2 (0.39) NR4A2KDM4EKMT2AMEN1POLB
SCHEMBL7497813 0.81 NR4A2 (0.43) NR4A2NPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662174-B2 BTK inhibitor HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2020-05-26 US disclosed
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 US disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 US disclosed
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 SHIONOGI & CO., LTD. (JP) 2010-04-22 US disclosed
US-4814344-A ANTIEMENTICS, ANTIPSYCHOTICS GLAXO GROUP LIMITED 1989-03-21 US disclosed
EP-0266899-A2 Indole derivatives GLAXO GROUP LIMITED (GB) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662174-B2 BTK inhibitor BTK, SYK, LYN BRD4 634/4885L3MBTL1 2099/4885NR4A2 3412/4885
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 MMP13, MMP3, MMP26 BRD4 3088/4885L3MBTL1 1343/4885NR4A2 2694/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN BRD4 634/4885L3MBTL1 2099/4885NR4A2 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.